Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tktom who wrote (3956)	10/18/2015 12:25:46 PM
From: rkrw	Read Replies (1) \| Respond to of 4474

Oh well. With or without Ariad, this is really exciting news. npr.org

To: tktom who wrote (3956)	10/19/2015 6:37:07 PM
From: Biomaven	Read Replies (1) \| Respond to of 4474

The company doesn't have the money or the expertise to develop pona in any neurodegenerative disease. This is something best left to ISPs. The potential in ALS is purely theoretical - it is because pona inhibits RIPK1 and this is a crucial kinase involved with necroptosis, which researchers at Columbia discovered was how the motor neurons appeared to be killed. I actually emailed the researcher there about pona as a RIPK inhibitor some time back - don't know if they ever tried it in their stem-cell model. But at this point it is only speculation - have to actually run the experiment to see if it works in their model. Likely not particularly relevant to the company's stock price in my view, although that could change if further research gets published. Peter